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Protein phosphatase-2A (PP2A) activity, which is compromised in Alzheimer disease brain, is regu-
lated by two endogenous inhibitors, one of them being I2PP2A, a 277 amino acid long protein also
known as SET. Here we report that both the amino terminal fragment (I2NTF; aa 1–175) and the car-
boxy terminal fragment (I2CTF; aa 176–277) of I2PP2A inhibit PP2A by binding to its catalytic subunit
PP2Ac and cause hyperphosphorylation of tau. The C-terminal acidic region in I2CTF and Val 92 in
I2NTF are essential for their association with PP2Ac and inhibition of the phosphatase activity.
Structured summary of protein interactions:
I2PP2A physically interacts with PP2A-C by anti tag coimmunoprecipitation (view interaction 1, 2)
I2PP2A physically interacts with PP2A-C by pull down (view interaction 1, 2)
PP2A-A physically interacts with PP2A-B and PP2A-C by pull down (view interaction)
 2011 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Abnormal hyperphosphorylation and aggregation of microtu-
bule associated protein tau into paired helical ﬁlaments/neuroﬁ-
brillary tangles is a hallmark of Alzheimer disease (AD) and
related neurodegenerative disorders, called tauopathies [1–3].
The hyperphosphorylated tau sequesters normal tau, MAP1 and
MAP2, which results in the breakdown of the microtubule network
and, probably in a progressive retrograde degeneration of the
affected neurons [4].
Protein phosphatase 2A (PP2A) is a heterotrimeric enzyme, con-
sisting of one catalytic C subunit, one scaffolding A subunit, and one
of several structurally distinct, regulatory B subunits [5]. The phos-
phorylation of tau that suppresses its microtubule binding and
assembly activities in adult mammalian brain is primarily regu-
lated by PP2A [6]. PP2A regulates tau phosphorylation, both directly
as tau phosphatase and indirectly by regulating the activities of
several tau kinases which include CaM Kinase II, PKA, MAP kinaseon behalf of the Federation of Euro
in phosphatase-2A; MEK1/2,
ed kinase; PHAP1, putative
d protein-1
al).
rst authorship.kinase (MEK 1/2), extracellular regulated kinase (ERK 1/2), GSK-
3b, and P70S6 kinase [7]. PP2A activity in AD brain is decreased [8].
The activity of PP2A is regulated by an inhibitor protein, I2PP2A
[9–11]; This protein, also known as SETa, TAF-1b, and PHAPII pro-
tein [12–14] was discovered as a translocated gene fused to the
CAN gene in a patient with acute undifferentiated leukemia [14].
I2PP2A is a 277 amino acid long polypeptide with an apparent
molecular weight of 39 kDa in SDS–PAGE. This protein is widely
expressed in various tissues and localizes primarily in the nucleus
[12,15,16] where it has been reported to block DNase activity and
acetylation of histones [17]. Previously, we showed that I2PP2A is
selectively cleaved at N175 into I2NTF (N-terminal fragment) and
I2CTF (C-terminal fragment) and translocated from the neuronal nu-
cleus to the cytoplasm, co-localized with neuroﬁbrillary tangles in
the affected areas of AD brain [18]. However, the exact molecular
mechanism of the inhibition of PP2A activity and generation of
abnormal hyperphosphorylation of tau by I2PP2A in the cell was
not understood. The present study shows that I2PP2A inhibits
PP2A activity dose-dependently and cleavage of this inhibitor into
I2NTF and I2CTF not only results in its translocation from the cell nu-
cleus to the cytoplasm but also potentiates its inhibitory activity,
for each of these two fragments can interact with the PP2A cata-
lytic subunit PP2Ac. I2CTF interacts with PP2Ac through its highly
acidic C-terminal domain. Interaction of I2NTF with PP2Ac and its
ability to inhibit the phosphatase activity is completely inhibited
when valine 92 in the inhibitor is mutated to alanine.pean Biochemical Societies.
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For generation of I2PP2A and its deletion mutant plasmids, GST
pull-down assays, coimmunoprecipitation, PP2A activity assays,
and immunocytochemical staining, see Supplementary data.
3. Results
3.1. I2
PP2A interaction with PP2Ac subunit
I2PP2A was previously shown to inhibit PP2A activity in vitro
[9,11]. To date, it is not clear whether I2PP2A can decrease PP2A
activity in cells and whether this reduction involves inhibition of
the PP2A expression level. To address to this question, we carried
out transient transfection of NIH3T3 cells with different amounts
of pCMV2B-I2PP2A. After 48 h transfection the cell lysates were col-
lected and one half of the sample was employed for Western blots
(Fig. 1A and B), whereas the other half was subjected to immuno-Fig. 1. Inhibition of PP2A activity by I2PP2A and its interaction with PP2Ac. (A) NIH3T3 cell
I2PP2A or, as a control, with vector alone. After 48 h transfection, cells were lysed and expre
blots. (B) The relative PP2Ac expression level was normalized by the expression of b-ac
amounts of expression of I2PP2A in NIH3T3 cells. One way ANOVA, P = 0.1369; t-test, vecto
PP2A was immunoprecipitated from cell lysates with anti-PP2Ac and the phosphatase a
activity in a pCMV2B-I2PP2A dose-dependent fashion. ⁄P < 0.05 compared with control. (D)
was incubated with Sepharose 4B beads bearing GST, GST-I2PP2A, or GST-PP2A-A. After wa
GST-I2PP2A and GST-PP2A-A used in pull down assay are shown in the lowest panel. GST-I2
subunit) or PR65a (PP2A A regulatory subunit). From left to right, Lane 2 (Ext.) is inpu
indicated on the left of the panel. Error bars in panels B and C indicate means ± SE; n =precipitation with anti-PP2Ac, followed by PP2A activity assay
(Fig. 1C). The FLAG-tagged I2PP2A expression in transfected cells in-
creased with the amount of DNA used for transfection (Fig. 1A). The
expression of PP2Ac, however, was not altered (Fig. 1B), suggesting
that the decrease in PP2A activity in transfected cells (Fig. 1C) was
due to PP2A inhibition and not to a reduction of the PP2A expres-
sion level.
I2PP2A was previously shown to inhibit PP2A1 (the ABC
complex), PP2A2 (the AC dimer), and PP2Ac (the C subunit) in a
non-competitive manner [9,19]. However, no direct evidence was
reported to conﬁrm this association. To study the interaction
between PP2A and I2PP2A, in vitro pull-down assays were carried
out using bacterially expressed GST alone (negative control),
GST-PP2A-A (positive control), or GST-I2PP2A. Rat brain extract as
the source of PP2A holoenzyme was added to puriﬁed GST-PP2A-
A, GST-I2PP2A, or GST alone, on glutathione Sepharose 4B beads
and the interactions were detected by Western blots developed
with antibodies to PP2A subunits A, B, or C. We found that I2PP2As were transfected with different amounts of pCMV2B-I2PP2A to express FLAG-tagged
ssion of PP2Ac, I2PP2A, and, as a loading control, b-actin were determined byWestern
tin. PP2Ac expression level did not show any signiﬁcant difference among different
r vs. 1 lg, P = 0.2189; vector vs. 2 lg, P = 0.5031; vector vs. 3 lg cDNA, P = 0.1992. (C)
ctivity assayed colorimetrically using pNPP as a substrate. I2PP2A inhibited the PP2A
GST-pull down assay. Rat brain extract (Ext.), used as a source of PP2A holoenzyme,
shing, bound PP2Ac, PP2A-B, and PP2A-A were detected by Western blots. The GST,
PP2A pulled down PP2Ac (PP2A catalytic subunit) but not PR55a (PP2A Ba regulatory
t, and Lane 3 (GST/Ext.) is a negative control. Positions of protein size markers are
3.
Fig. 2. Intracellular localization of I2FL, I2NTF, and I2CTF with reference to tau. (A) I2FL-myc, I2NTF-myc, and I2CTF-myc cDNA were generated using pEGFP-N3/I2PP2A (wt) as a template.
The PCR inserts as well as pcDNA3.1 were digested with BamHl and Xhol. The products were subsequently ligated into pcDNA3.1 vector and transformed into E. coli DH4-a.
(B) After ampliﬁcation, the puriﬁed plasmids were digested with BamHl and Xhol, separated by electrophoresis, and sequenced. (C) Left panel: Western blots speciﬁc for the
C-terminal myc tag of each protein conﬁrmed the expression of I2FL and I2NTF. Right panel: Western blots speciﬁc for the C-terminal myc tag of each protein conﬁrmed the
expression of I2FL and I2CTF. (D) Immunocytochemical staining of HEK293FT cells transfected with GFP-Tau and pcDNA3.1 or pcDNA3.1-I2FL, -I2NTF, or -I2CTF. I2FL tagged with c-
myc was localized exclusively in the nucleus of HEK293FT cells. I2NTF tagged with c-myc was diffused all over the HEK293FT cells. I2CTF tagged with c-myc, although
concentrated in the nucleus, was also found distributed within the cytoplasm. Magniﬁcation bar = 10 lm.
L. Arnaud et al. / FEBS Letters 585 (2011) 2653–2659 2655could pull down PP2Ac but not PP2A-A or PP2A-B subunits
(Fig. 1D). These ﬁndings suggest that I2PP2A interacts with the
PP2A catalytic subunit rather than the PP2A regulatory subunits
PP2A-A or PP2A-B.3.2. I2FL, I2NTF and I2CTF localize differently in HEK293FT cells
Previously we reported that in AD brain I2PP2A is selectively
cleaved at N175 and is translocated from the neuronal nucleus to
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aa1–175) or C-terminal fragment (I2CTF, aa176–277) or both can
translocate from the cell nucleus to the cytoplasm, we generated
three constructs corresponding to I2PP2A full length (I2FL), I2NTF,
and I2CTF, each tagged with myc, and inserted them in pcDNA3.1
vector (Fig. 2A) for expression in eukaryotic cells. To conﬁrm the
integrity of the constructs, the plasmids were multiplied in dH5a
Escherichia coli, puriﬁed and digested by BamHI and Xhol restric-
tion enzymes. The resulting DNA fragments were separated and
extracted from 1% agarose gel (Fig. 2B). The accuracy of the DNA
fragments was attested with subsequent sequencing. Finally, the
plasmids were transfected either in HEK293FT cells or NIH3T3 cells
and by Western blot analysis we conﬁrmed the expression of myc-
tagged I2FL, I2NTF, and I2CTF, at 39 kDA, 22 kDa, and 20 kDa apparent
molecular weight, respectively (Fig. 2C).
To assess the intracellular localization, we co-transfected
HEK293FT cellswith pcDNA3.1-I2FL and its fragmentswith an exclu-
sively cytoplasmic GFP fused tau protein. Then, 72 h post-transfec-
tion, the HEK293FT cells were ﬁxed with 4% paraformaldehyde
solution and analyzed by immunocytochemistry. The antibody to
myc recognized the exogenously expressed I2PP2A. While as ex-
pected I2FL was found within the nucleus, I2NTF and I2CTF were found
diffused both in the nucleus and the cytoplasm (Fig. 2D).
3.3. PP2Ac co-immunoprecipitates with I2FL, I2NTF, and I2CTF
Employing GST-pull down assays we showed above (Fig. 1D)
that in vitro I2FL could interact with PP2Ac but not with PP2A-A
or PP2A-B. To conﬁrm this interaction in cells, HEK293FT cells were
transfected with myc-tagged I2FL, I2NTF, or I2CTF for 72 h, followed by
immunoprecipitation with anti-myc from these cell lysates and
analysis by Western blots. PP2Ac co-immunoprecipitated with
I2FL as well as I2NTF and I2CTF (Figs. 3A and B). These ﬁndings sug-
gested that cleavage of I2PP2A into I2NTF and I2CTF could result in
an increased inhibition of PP2A activity.
3.4. Inhibition of PP2A activity and generation of hyperphosphorylated
tau by I2FL, I2NTF, and I2CTF
Next we proceeded to assess the effect of interactions of I2FL,
I2NTF and I2CTF with PP2A on the phosphatase activity and on phos-
phorylation of tau. A previous study had reported that I2PP2A inhib-
its PP2A through its amino terminal region [12]. We, therefore, ﬁrstFig. 3. Co-immunoprecipitation of PP2Ac with I2FL, I2NTF, or I2CTF. HEK293FT cells transfect
was used for immunoprecipitation. The pulled down proteins were separated on SDS–pol
pore size and analyzed byWestern blots. (A) Upper row:Western blots on the 0.45 lm PV
0.22 lm PVDF membrane developed with c-myc tag antibody. I2FL, I2NTF, and I2CTF were
blots developed with anti-PP2Ac. NC = negative control, i.e., non-treated with the vectorexamined whether I2NTF could inhibit PP2A activity. We transfected
HEK293FT cells with pcDNA3.1-I2FL, -I2NTF, or vector alone for 72 h,
and then assayed okadaic acid sensitive PP2A activity towards
pSer199 tau [20] in the cell lysates. We found that PP2A activity
was reduced to 70% and 50% in I2FL and I2NTF transfected cells,
respectively (Fig. 4A). In order to study the effect of this PP2A inhi-
bition on abnormal hyperphosphorylation of tau, we expressed in
tau441-stably transfected PC12 cells [21] I2FL or I2NTF for 72 h. We
then examined the phosphorylation of tau at multiple known path-
ological sites by Western blots of the cell lysates developed with
various phospho-speciﬁc antibodies. We found both in I2FL and in
I2NTF transfected cells abnormal hyperphosphorylation of tau at
M4 (Thr231/Ser235), pS404 (Ser404), PHF-1 (Ser396/404), and
12E8 (Ser262/356) sites. The tau hyperphosphorylation at M4,
PHF-1, and 12E8 sites, which are believed to be major sites in Alz-
heimer-type neuroﬁbrillary degeneration, was quite robust in cells
transfected with I2NTF (Fig. 4B and C).
Since both in the GST-pull down assays as well as the co-immu-
noprecipitation assays we had found that not only I2NTF but also
I2CTF interacted with PP2Ac (see above), we studied the effect of
I2CTF in comparison to I2FL on PP2A activity and hyperphosphoryla-
tion of tau in cells. In lysates of NIH3T3 cells which were transfec-
ted with I2FL, I2CTF, or vector alone, we found a 31% and 53%
reduction in PP2A activity, respectively (Fig. 5A). Tau441 stably
transfected PC12 cells transfected with pcDNA3.1-I2FL or -I2CTF
showed a marked increase in abnormal hyperphosphorylation of
tau at M4 (Thr231/Ser235), pS404 (Ser404), pS262 (Ser262), and
12E8 (Ser262/346) sites (Fig. 5B and C).
3.5. Domains of I2
PP2Ainvolved in its binding to PP2A catalytic subunit
Finally, based on the structural features of I2PP2A (TAF-Ib) charac-
terized by a subtype speciﬁc N-terminal region, a coiled-coil region
involved in dimerization of TAF-I, a putative nuclear localization
signal, and a long stretch of acidic amino acids at C-terminal ends
[12,22], we attempted to deﬁne the PP2Ac binding domain in
I2PP2A. For this purpose, based on the structure, a series of the dele-
tion mutants of I2PP2A, I2NTF, I2CTF and F4 corresponding to the C-ter-
minal acidic region were generated (Fig. 6A). During these studies
Val 92 in I2NTF was accidently mutated to Ala. While we corrected
this mutation by mutagenesis, we also decided to study the effect
of this point mutation on interaction of I2NTF with PP2A. In vitro
pull-down assays were carried out with bacterially expressed GSTed to overexpress c-myc-tagged I2FL, I2NTF or I2CTF were lysed and c-myc tag antibody
yacrylamide gels, then transferred onto two stacked PVDF membranes of decreasing
DF membrane developed with c-myc tag antibody. Lower row:Western blots on the
all immunoprecipitated with the c-myc antibody (see framed bands). (B) Western
. Positions of protein molecular markers are shown on the left of the blots.
Fig. 4. Inhibition of PP2A activity by I2FL and I2NTF. (A) Relative PP2A activity in
transiently transfected HEK293FT cells with N-terminal myc tagged I2FL and I2NTF.
I2FL and I2NTF reduced PP2A activity to 70% and 50%, respectively, in HEK293FT
cells. ⁄P < 0.05 compared with the vector transfection control. (B) Tau441 stably
transfected PC12 cells were transiently transfected to express myc tagged I2FL or
I2NTF and tau phosphorylation at M4 (pT231/pS235), pS404, PHF-1 (pS396/404) and
12E8 (pS262/356), total tau (R134d), as well as transfected I2PP2A were detected by
Western blots from same amounts of lysates. The myc-tagged proteins were
detected with anti-myc monoclonal 9E10 (1:100 in 5% defatted milk and 0.1%
Tween-20) from Millipore/Chemicon. (C) The level of phosphorylated tau was
quantiﬁed by densitometry and normalized to the amount of total tau. ⁄P < 0.05
compared with the vector transfection control. Positions of protein size markers are
indicated on the left of the blots. Positions of I2FL and I2NTF bands are labeled with
arrows. NSB = non-speciﬁc band.
Fig. 5. Inhibition of PP2Ac activity by I2FL and I2CTF. (A) Relative PP2A activity in
transiently transfected cells with C-terminal myc tagged constructs was detected as
described in Fig. 1C. I2FL reduced PP2A activity to 69% whereas I2CTF inhibited PP2A
activity to 47%. ⁄P < 0.05 compared with the vector transfection control. (B) Tau
phosphorylation at M4 (pT231/pS235), pS404, pS262, 12E8 (pS262/356), total tau
(R1334D) and I2PP2A were detected by Western blots from same amounts of lysates
from I2FL and I2CTF transfected cells. The myc-tagged proteins were detected with
anti-myc monoclonal 9B11 (1:1000 in 5% defatted milk and 0.1% Tween-20). (C) The
level of phosphorylated tau was quantiﬁed by densitometry and normalized using
the amount of total tau. ⁄P < 0.05 compared with the vector transfection control.
The rest of the details are the same as in Fig. 4.
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added to puriﬁed GST fusion proteins or GST alone on glutathione
Sepharose 4B beads and PP2A catalytic subunit that was pulled
down by these beads was detected by Western blots. The results
showed that I2PP2A and its mutants containing C-terminal acidic re-
gion (I2PP2AF4 and I2CTF) had the ability of binding with PP2Ac,
whereas, the mutation of valine 92 to alanine in the leucine rich re-
gion of I2NTF lost its PP2Ac binding ability (Fig. 6B and C). Thus, the
minimal region of I2CTF required for the binding of PP2Ac is localized
at the C-terminal acidic region (amino acid 225–277), and Val 92 in
I2NTF is not only necessary for the binding but also for its inhibitory
activity (Fig. 6D).
4. Discussion
I2PP2A/SET is a multifunctional protein. It is believed to have a
nuclear localization signal between amino acid residues 168–181
and is imported in the cell nucleus mainly by importin alpha-3[23]. In its primary location in the cell nucleus it protects cells both
by inhibiting DNAse [24] and acetylation of histones [17]. Translo-
cation of I2PP2A from the nucleus to the cytoplasm has been re-
ported to be cytotoxic and exacerbates DNA damage [23].
Generation of intracytoplasmic juxtamembrane domains of APP
and APLP2 by caspase has also been shown to lead to the translo-
cation of I2PP2A from the nucleus to the cytoplasm and cell death
[25]. In vitro studies had shown that I2PP2A was also a potent inhib-
itor of PP2A [19] and that this inhibitory activity was localized in
its amino terminal region [26]. Previously, we discovered that in
AD brain I2FL is selectively cleaved at N175 into I2NTF and I2CTF,
and translocated from the neuronal nucleus to the cytoplasm
where it colocalizes with abnormally hyperphosphorylated tau/
neuroﬁbrillary tangles [18]. A subsequent study showed that the
cleavage of I2PP2A at N175 can be catalyzed by a lysosomal/endo-
somal enzyme, asparaginyl endopeptidase (also known as legu-
main) which occurs during cerebral acidosis caused by ischemic
stroke or seizures [27]. However, neither the exact molecular
mechanism by which I2PP2A inhibits PP2A activity nor how its
cleavage into I2NTF and I2CTF contributes to abnormal hyperphosph-
orylation of tau were understood. The present study for the ﬁrst
time shows that I2PP2A decreases PP2A activity in the cell by
Fig. 6. Identiﬁcation of minimal and critical regions of I2PP2A required for interaction with PP2Ac. (A) Schematic diagram of the constructs of functional domains of I2PP2A
employed for the interaction studies. (B, C) GST-pull down assays with rat brain extract as a source of PP2A holoenzyme. The pull down assays were carried out using 0.5 lg of
GST-fusion protein per mg brain extract, except in cases of GST-I2CTF (0.1 lg was employed), and GST alone (double the amount, i.e., 1 lg was employed). I2CTF, F4, and I2NTF
but not I2NTFV92A interacted with PP2Ac. (D) Relative PP2A activity in transiently transfected NIH3T3 cells with C-terminal myc tagged constructs I2NTF-myc can reduce PP2A
activity and mutation of V92 to A in I2NTF results in a complete loss of this inhibitory activity. ⁄P < 0.05.
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expression of PP2Ac. Furthermore, while I2FL localizes in the cell
nucleus, both I2NTF and I2CTF are diffused into the cytoplasm where
they interact with PP2A through PP2Ac and inhibit the phospha-
tase activity. I2NTF and I2CTF appear to be quite robust in inhibiting
PP2A activity and causing abnormal hyperphosphorylation of tau.
I2CTF interacts with PP2Ac through its carboxy terminal acidic re-
gion. In I2NTF valine 92 is required for its interaction with PP2Ac
and inhibition of the phosphatase activity. The inhibition of PP2A
activity by I2FL, INTF, and I2CTF was observed in all three cell lines,
i.e., NIH3T3, HEK293FT, and PC12 cells, studied.
Because of the small sizes of I2NTF and I2CTF as compared with
I2FL, these proteins transferred to the PVDF membrane at quite var-
iable rates and, therefore, it was not possible to normalize the inhi-
bition of PP2A activity or hyperphosphorylation of tau from the
intensity of the protein bands seen in Western blots. However,
hyperphosphorylation of tau at various sites observed in I2NTF or
I2CTF as compared with I2FL-transfected cells indicated that the
two fragments of I2PP2A probably inhibited PP2A activity towards
phosphotau in a substrate-speciﬁc manner. Relative to I2FL, the
expression of I2NTF caused a high level of hyperphosphorylation
of tau at Thr231/Ser235 (M4 site), Ser262/356 (12E8 site), and
Ser396/404 (PHF-1 site) but not at Ser404, and I2CTF at Thr231/
Ser235 (M4 site). Previously, in an in vivo study in rat, we showed
that I2CTF caused hyperphosphorylation of tau at Ser396 [28].In AD brain the activity of PP2A is compromised [8] and tau is
abnormally hyperphosphorylated [1,3]. The AD abnormally hyper-
phosphorylated tau probably disrupts the microtubule network
and leads to neurodegeneration by sequestration of normal tau
as well as microtubule associated proteins MAP1 and MAP2 [4].
In the present study, the PP2A inhibition by I2PP2A, especially
I2NTF and I2CTF, resulted in abnormal hyperphosphorylation of tau
at Thr231/Ser235, Ser262/356, and Ser396/404 in cultured cells.
These phosphorylation sites are known to inhibit binding of tau
to microtubules [7] and cause neurodegeneration, and cognitive
impairment [29]. Since the inhibition of PP2A by the carboxy ter-
minal region of I2PP2A was not previously known, based on the
present study, we expressed I2CTF in the brain and found inhibition
of PP2A activity, neurodegeneration associated with abnormal
hyperphosphorylation of tau, and intraneuronal accumulation of
Ab and impairment in spatial learning and memory in rats [28].
These in vivo ﬁndings on the PP2A inhibitory activity of I2CTF are
in agreement with the present study.
PP2A, which accounts for 70% of the total phosphoseryl/phos-
phothreonyl protein phosphatase activity in humanbrain, is thema-
jor tau phosphatase [30]. PP2A regulates phosphorylation of tau
both directly and by regulating the activities of several tau protein
kinases which include PKA, CaMKII, MEK1/2, ERK1/2, and p70S6 ki-
nase [7]. I2PP2A binds the neuronal cdk5 activator p35 and enhances
the ckd5/p35 activity [31]. Knockdown and overexpression of I2PP2A
L. Arnaud et al. / FEBS Letters 585 (2011) 2653–2659 2659in the brain have been found to decrease and increase GSK-3b activ-
ity, respectively [28,32]. Thus, a dysregulation of I2PP2A can have a
profound effect on affected neurons, both through activation of sev-
eral protein kinases and abnormal hyperphosphorylation of tau.
Besides I2PP2A, PP2A activity is also regulated bymethylation and
phosphotyrosinylation of PP2Ac and by I1PP2A, also known as PHAPI
(putative histocompatibility leukocyte antigen class II associated
protein-1), mapmodulin, pp32, and LANP [9]. Both mRNA and pro-
tein expressions of I1PP2A are elevated and the inhibitor is co-local-
ized with neuroﬁbrillary tangles in AD brain [18]. Demethylation of
PP2Ac, which decreases its activity, was reported in AD brain
[33,34]. Phosphorylation of PP2Ac at tyrosine 307, which inhibits
its activity, was found to be elevated in AD brain [35]. Microarray
analyses showed an upregulation of the expression of SET genes
in AD hippocampus [36]. While the mRNA and protein expressions
of I2PP2A are elevated in AD brain, reported by us previously [18], the
dual action of I2NTF and I2CTF in inhibiting PP2A activity shown in the
present study shows how the cleavage and translocation of this
inhibitor could work as the last straw which broke the camel’s back
in producing neuroﬁbrillary degeneration in AD.
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